ERBB2 and non-small cell lung carcinoma: Doublet chemotherapy used to be the standard-of-care for HER2-mutated NSCLC, however, previous results including ours showed a discouraging result with the ORR of 10–43.5% and median PFS of 4.3–6 months [27].